Results 151 to 160 of about 182,500 (270)

Cutaneous Eruptions Associated With Tumour Infiltrating Lymphocyte Therapy: A Case Series

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Tumour‐infiltrating lymphocyte (TIL) therapy is a newly emerged effective treatment for advanced melanoma refractory to immune checkpoint inhibitors; however, its cutaneous adverse effects remain uncharacterized. We present the first case series describing dermatologic adverse effects associated with TIL therapy for malignant melanoma in five ...
Shannon C. Lyden   +9 more
wiley   +1 more source

Pembrolizumab‐Induced Subacute Cutaneous Lupus Erythematosus: A Case Report

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Subacute cutaneous lupus erythematosus (SCLE) is an increasingly recognized cutaneous immune‐related adverse event of immune checkpoint inhibitors. We report an 83‐year‐old woman who developed pruritic annular and polycyclic plaques 10 weeks after starting pembrolizumab for oropharyngeal squamous cell carcinoma.
Sebastiano Posenato   +5 more
wiley   +1 more source

Salvage Chemotherapy After Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. [PDF]

open access: yesIn Vivo
Fushimi C   +17 more
europepmc   +1 more source

Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT The prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) are simple markers that reflect immune and nutritional status. This retrospective study evaluated their prognostic significance in 276 patients with advanced hepatocellular carcinoma (HCC) who received first‐line lenvatinib. PNI and GNRI were calculated based on
Cheng‐Wei Kuo   +9 more
wiley   +1 more source

Composite Inflammatory Score for Predicting Progression‐Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First‐Line Toripalimab Plus Axitinib

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Routine inflammatory and nutritional markers may help stratify progression risk in metastatic clear cell renal cell carcinoma during immunotherapy‐based treatment. This single‐center retrospective study included 237 patients who received first‐line toripalimab plus axitinib therapy.
Yun‐Feng Wu   +4 more
wiley   +1 more source

Danvatirsen plus Pembrolizumab versus Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (PEMDA-HN): A Randomized, Phase II Trial. [PDF]

open access: yesClin Cancer Res
Saba NF   +10 more
europepmc   +1 more source

Bilateral Ophthalmoplegia After Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma

open access: yesThe Laryngoscope, EarlyView.
The role of immune checkpoint inhibition (ICI) therapy in the treatment of head and neck squamous cell carcinoma (HNSCC) is expanding with increased utilization of neoadjuvant and adjuvant pembrolizumab in the setting of locally advanced disease. This report describes the presentation and management of the first known case of pembrolizumab‐induced ...
Leonard E. Estephan   +3 more
wiley   +1 more source

Contemporary Treatment Patterns in Surgically Treated Temporal Bone Cancer

open access: yesThe Laryngoscope, EarlyView.
In a national cohort of 811 surgically treated temporal bone cancer patients, adjuvant radiation therapy was the most frequently utilized postoperative treatment (20.3%), while chemotherapy and immunotherapy were used far less frequently. Multimodal treatment, particularly combined parotidectomy and neck dissection, was strongly associated with higher ...
Raquel Rowell   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy